Congestive Heart Failure Drugs Market Size, Share & Trends Analysis Report By Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 5 Business Days
Congestive Heart Failure Drugs Market Growth & Trends
The global congestive heart failure drugs market size is expected to reach USD 20.23 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 14.60% from 2022 to 2030. The increase in the prevalence of congestive heart failure (CHF), the rising aging population leading to increased risk of disease, and growing research and development for better treatment approaches are the key factors augmenting the growth. In 2020, around 64.34 million people worldwide were suffering from heart failure. In addition, its estimated prevalence rate is high in patients with diseases such as diabetes and hypertension.
Increasing research and development for better treatment options is a major factor behind the presence of multiple products in the pipeline. Novo Nordisk’s Semaglutide, Zensun’s Neucardin, Bayer’s vericiguat, and AstraZeneca’s AZD4831 are among the prominent drug candidates. Moreover, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is expected to fuel market growth. For instance, in February 2022, Jardiance (empagliflozin) and in May 2020, Farxiga (dapagliflozin) received label expansion for the treatment of CHF.
Key players such as AstraZeneca; Bristol-Myers Squibb Company; Amgen Inc.; and Boehringer Ingelheim are strategically engaged in geographical expansions, regulatory approvals, collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For instance, in February 2021, AstraZeneca announced the approval of Forxiga (dapagliflozin) in China, indicated for CHF with or without type-2 diabetes. Before China, the drug was already approved in the U.S., Europe, and Japan for the same indication.
COVID-19 impacted the demand and supply of drugs, and patients faced difficulty in healthcare access, resulting in a decline in product demand amid the pandemic. Due to imposed restrictions, research and development saw a setback in clinical trial proceedings. However, after the pandemic, the industry regained its pace.
Congestive Heart Failure Drugs Market Report Highlights
Congestive Heart Failure Drugs Market Growth & Trends
The global congestive heart failure drugs market size is expected to reach USD 20.23 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 14.60% from 2022 to 2030. The increase in the prevalence of congestive heart failure (CHF), the rising aging population leading to increased risk of disease, and growing research and development for better treatment approaches are the key factors augmenting the growth. In 2020, around 64.34 million people worldwide were suffering from heart failure. In addition, its estimated prevalence rate is high in patients with diseases such as diabetes and hypertension.
Increasing research and development for better treatment options is a major factor behind the presence of multiple products in the pipeline. Novo Nordisk’s Semaglutide, Zensun’s Neucardin, Bayer’s vericiguat, and AstraZeneca’s AZD4831 are among the prominent drug candidates. Moreover, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is expected to fuel market growth. For instance, in February 2022, Jardiance (empagliflozin) and in May 2020, Farxiga (dapagliflozin) received label expansion for the treatment of CHF.
Key players such as AstraZeneca; Bristol-Myers Squibb Company; Amgen Inc.; and Boehringer Ingelheim are strategically engaged in geographical expansions, regulatory approvals, collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For instance, in February 2021, AstraZeneca announced the approval of Forxiga (dapagliflozin) in China, indicated for CHF with or without type-2 diabetes. Before China, the drug was already approved in the U.S., Europe, and Japan for the same indication.
COVID-19 impacted the demand and supply of drugs, and patients faced difficulty in healthcare access, resulting in a decline in product demand amid the pandemic. Due to imposed restrictions, research and development saw a setback in clinical trial proceedings. However, after the pandemic, the industry regained its pace.
Congestive Heart Failure Drugs Market Report Highlights
- In 2021, the ACE inhibitors segment held the largest share due to its high prescription rate and market penetration
- By drug class, the others segment is expected to be the fastest-growing segment over the forecast period due to the launch of sodium-glucose co-transporter 2 (SGLT2) inhibitors
- By distribution channel, the retail pharmacies segment is expected to witness lucrative growth over the forecast period due to its high compatibility with home care settings and prescription drugs
- North America was the largest revenue-generating region in 2021. This can be attributed to the presence of key players, favorable funding assistance, and increased patient awareness
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR's internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 CONGESTIVE HEART FAILURE DRUGS MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory Landscape
3.3 Market Driver Analysis
3.3.1 Rising prevalence of the disease
3.3.2 Growing geriatric population
3.3.3 New product approvals
3.3.4 Strong clinical drugs pipeline
3.4 Market Restraint Analysis
3.4.1 Availability of generic and off-label drugs in market
3.4.2 Poor reimbursement scenarios in developing countries
3.5 Industry Analysis - Porter's
3.6 PESTEL Analysis (Political & Legal, Economic, and Technological)
3.7 Pipeline Analysis, by Phase
CHAPTER 4 CONGESTIVE HEART FAILURE DRUGS MARKET: SEGMENT ANALYSIS, BY DRUG CLASS, 2018 - 2030 (USD MILLION)
4.1 Congestive Heart Failure Drugs Market: Drug Class Movement Analysis
4.2 ACE Inhibitors
4.2.1 ACE Inhibitors Market, 2018 - 2030 (USD Million)
4.3 Angiotensin 2 Receptor Blockers
4.3.1 Angiotensin 2 Receptor Blockersmarket, 2018 - 2030 (USD Million)
4.4 Beta Blockers
4.4.1 Beta Blockers Market, 2018 - 2030 (USD Million)
4.5 Diuretics
4.5.1 Diuretics Market, 2018 - 2030 (USD Million)
4.6 Aldosterone Antagonists
4.6.1 Aldosterone Antagonists Market, 2018 - 2030 (USD Million)
4.7 Inotropes
4.7.1 Inotropes Market, 2018 - 2030 (USD Million)
4.8 Others
4.8.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 5 CONGESTIVE HEART FAILURE DRUGS MARKET: SEGMENT ANALYSIS, BY DISTRIBUTION CHANNEL, 2018 - 2030 (USD MILLION)
5.1 Congestive Heart Failure Drugs Market: Distribution Channel Movement Analysis
5.2 Hospital Pharmacies
5.2.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
5.3 Retail Pharmacies
5.3.1 Retail Pharmacies Market, 2018 - 2030 (USD Million)
5.4 Online Pharmacies
5.4.1 Online Pharmacies Market, 2018 - 2030 (USD Million)
CHAPTER 6 CONGESTIVE HEART FAILURE DRUGS MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Regional Market Snapshot
6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
6.4.1 North America
6.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 U.S. Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Canada Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2 Europe
6.4.2.1 Europe Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.2 U.K.
6.4.2.2.1 U.K. Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Germany Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.4 Spain
6.4.2.4.1 Spain Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.5 France
6.4.2.5.1 France Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.6 Italy
6.4.2.6.1 Italy Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.2 Japan
6.4.3.2.1 Japan Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.3 China
6.4.3.3.1 China Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.4 India
6.4.3.4.1 India Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.5 South Korea
6.4.3.5.1 South Korea Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.6 Australia
6.4.3.6.1 Australia Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Brazil Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Mexico Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Argentina Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5 MEA
6.4.5.1 MEA Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 South Africa Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Saudi Arabia Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 UAE Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
CHAPTER 7 CONGESTIVE HEART FAILURE DRUGS MARKET: COMPETITIVE ANALYSIS
7.1 Public Companies
7.1.1 Company Market Position Analysis
7.1.2 Competitive Dashboard Analysis
7.1.3 Strategic Framework
7.2 Private Companies
7.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
7.2.2 Regional Network Map
7.3 Company Profiles
7.3.1 BAYER AG
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 NOVARTIS AG
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 MERCK & CO., INC.
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 Product Benchmarking
7.3.3.4 Strategic Initiatives
7.3.4 ASTRAZENECA
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic Initiatives
7.3.5 BRISTOL-MYERS SQUIBB COMPANY
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 AMGEN INC.
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 BOEHRINGER INGELHEIMINTERNATIONAL GMBH
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 PFIZER, INC.
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 JOHNSON & JOHNSON SERVICES, INC.
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
7.3.10 OTSUKA PHARMACEUTICAL CO., LTD.
7.3.10.1 Company Overview
7.3.10.2 Financial Performance
7.3.10.3 Product Benchmarking
7.3.10.4 Strategic Initiatives
7.3.11 ELI LILLY AND COMPANY
7.3.11.1 Company Overview
7.3.11.2 Financial Performance
7.3.11.3 Product Benchmarking
7.3.11.4 Strategic Initiatives
7.3.12 NOVO NORDISKA/S
7.3.12.1 Company Overview
7.3.12.2 Financial Performance
7.3.12.3 Product Benchmarking
7.3.12.4 Strategic Initiatives
1.1 Market Segmentation and Scope
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR's internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 CONGESTIVE HEART FAILURE DRUGS MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Penetration and Growth Prospect Mapping
3.2 Regulatory Landscape
3.3 Market Driver Analysis
3.3.1 Rising prevalence of the disease
3.3.2 Growing geriatric population
3.3.3 New product approvals
3.3.4 Strong clinical drugs pipeline
3.4 Market Restraint Analysis
3.4.1 Availability of generic and off-label drugs in market
3.4.2 Poor reimbursement scenarios in developing countries
3.5 Industry Analysis - Porter's
3.6 PESTEL Analysis (Political & Legal, Economic, and Technological)
3.7 Pipeline Analysis, by Phase
CHAPTER 4 CONGESTIVE HEART FAILURE DRUGS MARKET: SEGMENT ANALYSIS, BY DRUG CLASS, 2018 - 2030 (USD MILLION)
4.1 Congestive Heart Failure Drugs Market: Drug Class Movement Analysis
4.2 ACE Inhibitors
4.2.1 ACE Inhibitors Market, 2018 - 2030 (USD Million)
4.3 Angiotensin 2 Receptor Blockers
4.3.1 Angiotensin 2 Receptor Blockersmarket, 2018 - 2030 (USD Million)
4.4 Beta Blockers
4.4.1 Beta Blockers Market, 2018 - 2030 (USD Million)
4.5 Diuretics
4.5.1 Diuretics Market, 2018 - 2030 (USD Million)
4.6 Aldosterone Antagonists
4.6.1 Aldosterone Antagonists Market, 2018 - 2030 (USD Million)
4.7 Inotropes
4.7.1 Inotropes Market, 2018 - 2030 (USD Million)
4.8 Others
4.8.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 5 CONGESTIVE HEART FAILURE DRUGS MARKET: SEGMENT ANALYSIS, BY DISTRIBUTION CHANNEL, 2018 - 2030 (USD MILLION)
5.1 Congestive Heart Failure Drugs Market: Distribution Channel Movement Analysis
5.2 Hospital Pharmacies
5.2.1 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
5.3 Retail Pharmacies
5.3.1 Retail Pharmacies Market, 2018 - 2030 (USD Million)
5.4 Online Pharmacies
5.4.1 Online Pharmacies Market, 2018 - 2030 (USD Million)
CHAPTER 6 CONGESTIVE HEART FAILURE DRUGS MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)
6.1 Definition & Scope
6.2 Regional Market Share Analysis, 2021 & 2030
6.3 Regional Market Snapshot
6.4 Market Size, & Forecasts, Revenue and Trend Analysis, 2021 to 2030
6.4.1 North America
6.4.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
6.4.1.2 U.S.
6.4.1.2.1 U.S. Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.1.3 Canada
6.4.1.3.1 Canada Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2 Europe
6.4.2.1 Europe Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.2 U.K.
6.4.2.2.1 U.K. Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.3 Germany
6.4.2.3.1 Germany Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.4 Spain
6.4.2.4.1 Spain Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.5 France
6.4.2.5.1 France Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.2.6 Italy
6.4.2.6.1 Italy Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3 Asia Pacific
6.4.3.1 Asia Pacific Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.2 Japan
6.4.3.2.1 Japan Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.3 China
6.4.3.3.1 China Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.4 India
6.4.3.4.1 India Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.5 South Korea
6.4.3.5.1 South Korea Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.3.6 Australia
6.4.3.6.1 Australia Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4 Latin America
6.4.4.1 Latin America Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.2 Brazil
6.4.4.2.1 Brazil Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.3 Mexico
6.4.4.3.1 Mexico Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.4.4 Argentina
6.4.4.4.1 Argentina Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5 MEA
6.4.5.1 MEA Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.2 South Africa
6.4.5.2.1 South Africa Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.3 Saudi Arabia
6.4.5.3.1 Saudi Arabia Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
6.4.5.4 UAE
6.4.5.4.1 UAE Congestive Heart Failure Drugs Market, 2018 - 2030 (USD Million)
CHAPTER 7 CONGESTIVE HEART FAILURE DRUGS MARKET: COMPETITIVE ANALYSIS
7.1 Public Companies
7.1.1 Company Market Position Analysis
7.1.2 Competitive Dashboard Analysis
7.1.3 Strategic Framework
7.2 Private Companies
7.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
7.2.2 Regional Network Map
7.3 Company Profiles
7.3.1 BAYER AG
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 NOVARTIS AG
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 MERCK & CO., INC.
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 Product Benchmarking
7.3.3.4 Strategic Initiatives
7.3.4 ASTRAZENECA
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic Initiatives
7.3.5 BRISTOL-MYERS SQUIBB COMPANY
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 AMGEN INC.
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 BOEHRINGER INGELHEIMINTERNATIONAL GMBH
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 PFIZER, INC.
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 JOHNSON & JOHNSON SERVICES, INC.
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
7.3.10 OTSUKA PHARMACEUTICAL CO., LTD.
7.3.10.1 Company Overview
7.3.10.2 Financial Performance
7.3.10.3 Product Benchmarking
7.3.10.4 Strategic Initiatives
7.3.11 ELI LILLY AND COMPANY
7.3.11.1 Company Overview
7.3.11.2 Financial Performance
7.3.11.3 Product Benchmarking
7.3.11.4 Strategic Initiatives
7.3.12 NOVO NORDISKA/S
7.3.12.1 Company Overview
7.3.12.2 Financial Performance
7.3.12.3 Product Benchmarking
7.3.12.4 Strategic Initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of Diseases
Table 4 Global Congestive Heart Failure Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 6 Global Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 9 North America Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 11 U.S. Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Canada Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 Canada Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Europe Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 15 Europe Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 16 Europe Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 18 Germany Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 U.K. Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 U.K. Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 21 France Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 22 France Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 23 Italy Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 24 Italy Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 Spain Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 26 Spain Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Asia Pacific Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 Asia pacific Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 30 Japan Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 31 Japan Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 32 China Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 33 China Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 India Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 India Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 36 South Korea Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 37 South Korea Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Australia Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 39 Australia Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Latin America Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 41 Latin America Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 42 Latin America Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Brazil Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 44 Brazil Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 45 Mexico Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 46 Mexico Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Argentina Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 48 Argentina Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Middle East & Africa Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 50 Middle East & Africa Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Saudi Arabia Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 52 Saudi Arabia Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 53 South Africa Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 South Africa Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 UAE Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 56 UAE Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of Diseases
Table 4 Global Congestive Heart Failure Drugs Market, By Region, 2018 - 2030 (USD Million)
Table 5 Global Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 6 Global Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 9 North America Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 10 U.S. Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 11 U.S. Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Canada Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 13 Canada Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Europe Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 15 Europe Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 16 Europe Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 18 Germany Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 19 U.K. Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 20 U.K. Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 21 France Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 22 France Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 23 Italy Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 24 Italy Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 25 Spain Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 26 Spain Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Asia Pacific Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 28 Asia Pacific Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 29 Asia pacific Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 30 Japan Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 31 Japan Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 32 China Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 33 China Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 34 India Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 35 India Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 36 South Korea Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 37 South Korea Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Australia Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 39 Australia Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 40 Latin America Congestive Heart Failure Drugs Market, By Country, 2018 - 2030 (USD Million)
Table 41 Latin America Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 42 Latin America Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Brazil Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 44 Brazil Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 45 Mexico Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 46 Mexico Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Argentina Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 48 Argentina Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Middle East & Africa Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 50 Middle East & Africa Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 51 Saudi Arabia Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 52 Saudi Arabia Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 53 South Africa Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 54 South Africa Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 55 UAE Congestive Heart Failure Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
Table 56 UAE Congestive Heart Failure Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Congestive Heart Failure Drugs Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Congestive Heart Failure Drugs Market snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook, revenue, 2021 (USD Million)
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Congestive Heart Failure Drugs Market driver impact
Fig. 14 Congestive Heart Failure Drugs Market restraint impact
Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 16 Industry Analysis - Porter's
Fig. 17 Strategy mapping
Fig. 18 Congestive Heart Failure Drugs Market: Drug Class outlook and key takeaways
Fig. 19 Congestive Heart Failure Drugs Market: Drug Class movement analysis & market share 2021 & 2030
Fig. 20 ACE Inhibitors Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Angiotensin 2 Receptor Blockers Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Beta Blockers Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Diuretics Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Aldosterone Antagonists Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Inotropes Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Congestive Heart Failure Drugs Market: Distribution Channel outlook and key takeaways
Fig. 28 Congestive Heart Failure Drugs Market: Distribution Channel movement analysis & market share 2021 & 2030
Fig. 29 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Retail and Speciality Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Congestive Heart Failure Drugs Market: Regional outlook and key takeaways
Fig. 33 Regional outlook, 2021 & 2030
Fig. 34 North America
Fig. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S.
Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Canada
Fig. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Europe
Fig. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 U.K.
Fig. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Germany
Fig. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 France
Fig. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Italy
Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Spain
Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific
Fig. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Japan
Fig. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
Fig. 56 China
Fig. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 India
Fig. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 South Korea
Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Australia
Fig. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Latin America
Fig. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Brazil
Fig. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Mexico
Fig. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Argentina
Fig. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Middle East & Africa
Fig. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 South Africa
Fig. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Saudi Arabia
Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 UAE
Fig. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Market differentiators
Fig. 81 Key company market share analysis, 2021
Fig. 82 Company market position analysis
Fig. 83 Competitive dashboard analysis
Fig. 84 Regional network map
Fig. 1 Congestive Heart Failure Drugs Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Congestive Heart Failure Drugs Market snapshot
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook, revenue, 2021 (USD Million)
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Congestive Heart Failure Drugs Market driver impact
Fig. 14 Congestive Heart Failure Drugs Market restraint impact
Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
Fig. 16 Industry Analysis - Porter's
Fig. 17 Strategy mapping
Fig. 18 Congestive Heart Failure Drugs Market: Drug Class outlook and key takeaways
Fig. 19 Congestive Heart Failure Drugs Market: Drug Class movement analysis & market share 2021 & 2030
Fig. 20 ACE Inhibitors Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Angiotensin 2 Receptor Blockers Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Beta Blockers Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Diuretics Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Aldosterone Antagonists Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Inotropes Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others Congestive Heart Failure Drugs Market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Congestive Heart Failure Drugs Market: Distribution Channel outlook and key takeaways
Fig. 28 Congestive Heart Failure Drugs Market: Distribution Channel movement analysis & market share 2021 & 2030
Fig. 29 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Retail and Speciality Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Congestive Heart Failure Drugs Market: Regional outlook and key takeaways
Fig. 33 Regional outlook, 2021 & 2030
Fig. 34 North America
Fig. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 U.S.
Fig. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Canada
Fig. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Europe
Fig. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 U.K.
Fig. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Germany
Fig. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 France
Fig. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Italy
Fig. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Spain
Fig. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific
Fig. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Japan
Fig. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
Fig. 56 China
Fig. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 India
Fig. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 South Korea
Fig. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Australia
Fig. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Latin America
Fig. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Brazil
Fig. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Mexico
Fig. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Argentina
Fig. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Middle East & Africa
Fig. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 South Africa
Fig. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Saudi Arabia
Fig. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 UAE
Fig. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Market differentiators
Fig. 81 Key company market share analysis, 2021
Fig. 82 Company market position analysis
Fig. 83 Competitive dashboard analysis
Fig. 84 Regional network map
